Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Q-VANT and In vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass

Q-Vant Biosciences

Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced that it has signed an agreement with In vitro Plant-tech AB, a Swedish plant cell cultivation company whose technology platform and manufacturing facilities will permit the sustainable production of Quillaja saponaria biomass within bioreactors. This collaboration will create an additional source of raw materials that will enhance the sourcing matrix of Q-VANT, adding the key benefit of flexibility of being able to produce it anywhere in the world. This is in line with the company’s strategy of guaranteeing the long-term sustainability and continuity of supply for saponin-based adjuvants including QS-21 for the pharmaceutical markets. QS-21 is considered the “Gold Standard” adjuvant for enhancing immune response to vaccine antigens and is a vital component in more than 17 human vaccine candidates, including the FDA-approved GSK Shingrix® shingles vaccine and the WHO-authorized, GSK Mosquirix® malaria vaccine. In addition, saponin-based adjuvants are a key component in the Novavax COVID-19 vaccine, which has been shown to be highly effective in clinical trials and has recently been authorized for emergency use by the European Union (EU) and the World Health Organization (WHO). QS-21 is traditionally extracted from the bark of mature trees native to Chile known as the Quillaja saponaria — a harvesting process that negatively impacts the forest and the sustainability of the resource. Today, with regulatory restrictions on deforestation of this tree, and projected demand for QS-21 in the billions of doses annually, shortages of QS-21 are affecting the pharmaceutical market’s ability to meet the surging need for vaccine dosages globally. Q-VANT’s Q-SAP™ (Quillaja Sustainable Adjuvant Platform) is a technology platform combining computational learning techniques and a proprietary multi-step purification process to systematically enhance Quillaja sourcing options and to drive extremely effective outputs. The first of its kind, Q-SAP enables Q-VANT to obtain adjuvant products from a wide range of Quillaja-based plant materials, which can increase production volumes by as much as 1,000 times, leading to billions of doses in a 100% sustainable way. “ In vitro Plant-tech’s plant cell technology experts have over 25 years of experience,” said Doug Klaiber, the CEO of Q-VANT. “Their expertise coupled with their cell culture platform and production capabilities will enhance our supply and is complementary to our mission to meet the growing demand and secure supply chain continuity for delivering the world with billions of doses of 100% sustainable QS-21 and other saponin-based adjuvants.” “ In vitro Plant-tech is delighted to offer our plant cell cultivation technology, cell cultivation and enhancement platforms, and production capabilities to support Q-VANT on their mission to meet the growing demand for QS-21 and other saponin-based adjuvants,” said Anna Holefors, founder and CEO of In Vitro Plant-tech. “We look forward to paving the path for a fully sustainable QS-21 production platform and helping in the development and production of life saving vaccines.” About In vitro Plant-tech: In vitro Plant-tech is a research derived company, specializing in development and production of innovative active ingredients using the plant cell cultivation (PCC) technology. This technology enables sustainable production of uniform, customised, high quality plant material. As experts within PCC, we have developed a metabolic enhancement technology (MET) platform which enables optimised production and accumulation of bioactive substances. The company's products are used in the pharmaceutical, cosmetic, and food industries. The company also provides contract biomanufacturing and production services. For more information, visit www.invitroplanttech.se. About Q-VANT Biosciences Q-VANT is a privately held biosciences company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The company’s next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000 times – enabling the production of billions of doses annually to meet today’s increasing global market demand. Led by a team with unrivaled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com. Contact Details Erin O'Brien +1 401-490-9700 erin.obrien@svmpr.com Company Website https://q-vant.com/

March 08, 2022 07:00 AM Eastern Standard Time

Electronic Caregiver Presents Next Generation of Remote Patient Monitoring Technology With Virtual Caregiver at 2022 HIMSS Global Health Conference

Electronic Caregiver

Electronic Caregiver, a national digital health technology and services company, will debut Addison, the Virtual Caregiver, at the 2022 HIMSS Global Health Conference in Orlando, Florida, March 14-18. Addison is the next generation of remote patient monitoring (RPM) technology and offers a solution to the global caregiver crisis and the ongoing COVID-19 challenges by providing health care management outside the doctor’s four walls. Addison, anticipated to be released later this year, is a state-of-the-art, 3D-animated caregiver with an endearing personality. The Virtual Caregiver is designed to engage with and help monitor the health of aging and chronically ill clients, as well as child patients via touch-screen devices strategically placed throughout a residence. “Addison is a revolutionary new tool for use by providers to optimize patient care – monitoring, increasing treatment adherence, and improving health outcomes,” said Electronic Caregiver CEO Anthony Dohrmann. “Whether a patient with one or more morbidities requires assistance at home to follow complex medication regimens, comply with physical therapy, monitor vitals, or requires increased support for managing behavioral health conditions, Addison has the capabilities to extend care from provider to home.” Powered by Amazon Web Services (AWS) and Intel, Addison helps monitor patients’ health by providing voice-driven medication reminders, ensuring patients are following their doctor’s treatment plans, and offering 24/7 emergency response and telehealth services. Addison can also lead patients through the steps of recording a vital, such as blood pressure, oxygen saturation levels, and temperature, with the ability to share that information with designated providers and caregivers in real time. Addison gives a face and personality to the RPM experience. The Virtual Caregiver can also be customized to fit users’ preferences. Clients can choose from eight avatars of different ethnicities and genders to interact with, and Addison’s environment can mirror client lighting and weather automatically. Electronic Caregiver will present Addison, the Virtual Caregiver, in addition to its other RPM technology alongside Care Management company MD Revolution, Inc. at HIMSS Booth 4109. In 2020, Electronic Caregiver formed a partnership with MD Revolution, a provider of full-suite RPM and Chronic Care Management (CCM) solutions, to provide health practices with the technology and services to monitor patients remotely. “Through our highly productive partnership, we’re already delivering a 21st century health care experience for thousands of patients, and we’re confident our joint capabilities will scale to all the innovative health care providers in America,” said Kyle Williams, CEO of MD Revolution. “Our common goals are clear: to create more health care delivery capacity and to drive better patient outcomes. I’m confident we will continue to augment the traditional medical practice by building trust one patient at a time, one provider at a time.” MD Revolution offers Electronic Caregiver’s Pro Health, a 24/7 chronic care and monitoring system, as its preferred RPM device. The Pro Health includes a cellular-based console for the home and wearable wrist pendant for care support on the go. Like Addison, the Pro Health offers emergency response and health care management and can be paired with a multitude of Bluetooth devices to track vitals in real time. Devices are ordered, provisioned, and shipped directly to patients, with no up-front cost and no long-term commitment to the practice. MD Revolution has integrated the Pro Health into its HIPAA-compliant digital care management platform, called RevUp, which will be showcased during HIMSS. RevUp allows patient information to be securely monitored by a licensed care coordination team working as an extension of the provider practice. RevUp data is available with seamless, universal integration into the electronic health record (EHR), allowing for more proactive care by leveraging objective data and trend analysis. The solution also includes integrated care documentation, automated claims creation, and full-service marketing and enrollment services – resulting in more enrollments and faster reimbursement. Together, Electronic Caregiver and MD Revolution provide better outcomes, improved adherence, and simplified compliance management through sustainable telecare optimized for scale, economics, and services. Utilizing Electronic Caregiver’s technology, MD Revolution’s RevUp platform makes RPM implementation easy, supporting providers through the evolution of their practice. RevUp merges technology with traditional healthcare, seamlessly integrating with a provider’s day-to-day while upholding their practice's long-standing values. “We are reducing the number of office visits, ER visits, urgent care visits. So, the volume to medical facilities will very likely be reduced because we can monitor patients at home,” said MD Revolution client Dr. Edward Wingfield of Hamilton Cardiology Associates in New Jersey. “A lot of times, we bring patients in to just get a blood pressure or just to get a weight to make sure they are not going into heart failure. If all these things can be done remotely and we can act on it, it will cut medical costs.” About Electronic Caregiver Electronic Caregiver is a privately held digital health technology and services company headquartered in Las Cruces, NM (USA). ECG's mission is to design and deliver innovative, impactful telehealth products and services that bridge the chasm between the doctor's office and the patient's home to improve outcomes, expand access, and optimize resource allocation. ECG has been qualified as a technology solution provider in the Amazon Partner Network (APN). The company's solutions are available through health care organizations, physician practices, care management firms, home care agencies, and senior housing providers. www.electroniccaregiver.com About MD Revolution, Inc. MD Revolution, Inc. is an innovative Care Management company uniquely combining technology, services, and analytics to produce scalable, high-touch care models that enrich the patient-provider experience, improve the health of millions of patients, and enhance the profitable, effective practice of medicine for thousands of providers. MD Revolution’s remote care programs mitigate the challenges associated with meeting the requirements for Medicare’s Chronic Care Management (CCM), Remote Patient Monitoring (RPM), RPM for RHC/FQHC’s, Behavioral Health Integration (BHI), Annual Wellness Visits (AWV) and population health programs. Solutions are available as turn-key solutions, software-as-a-service, and through reseller partners. www.mdrevolution.com Contact Details Stephanie Guadian, Director of Public Relations +1 575-649-4604 sguadian@ecg-hq.com Alexia Severson, Public Relations Associate +1 575-993-9612 aseverson@ecg-hq.com

March 03, 2022 01:27 PM Mountain Standard Time

Image

Kadimastem Receives Grant for a Total Budget of NIS 10 Million ($3.1 million) from the Israeli Innovation Authority

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant from the Israel Innovation Authority (IIA) for a total budget of NIS 10 million ($3.1 million) and a net grant of NIS 4 million ($1.25 million). The grant will support the Company’s FDA IND enabling studies For its next clinical trial in ALS patients The funds will be used to advance the filing of an IND with the FDA by the end of 2022, to secure the approval of the FDA of the anticipated Phase IIa, US, multicenter, clinical trial protocol of AstroRx® for the treatment of ALS and expand the use of AstroRx® cell product for other neurological conditions such as multiple sclerosis and glaucoma. Kadimastem CEO Asaf Shiloni said, "This grant is an important expression of trust by the Israeli Innovation Authority in Kadimastem and the potential of our clinical, cell therapy platform to provide millions of patients worldwide with life-saving treatments. The Company is currently in one of the most significant periods in its history, both clinically and financially. We are scaling-up for a Phase IIa clinical trial of AstroRx® for ALS in the US as well as preparing to list on NASDAQ. This grant provides us with the necessary resources to advance both sets of plans.” Prof. Michel Revel, Chief Scientist of Kadimastem: "We thank the Innovation Authority for supporting Kadimastem, its work and its vision." This is the second grant awarded to Kadimastem in the past months by the IIA. The previous grant was earmarked for the scale-up of the production of AstroRx® as well as for creating a frozen, off-the-shelf product, to ensure the clinical quality of the product for patients worldwide. In 2019, Kadimastem completed a first-of-its-kind, Phase I/IIa clinical trial of AstroRx®, whereby the treatment was injected into the spinal cord fluid of 10 patients in a standard lumbar puncture procedure. AstroRx® showed high safety profile and significantly slowed the rate of disease progression for 3 months following treatment, as measured by the ALSFRS-R. Dr. Michal lzrael, VP of R&D said, “The grants the Company has received from the IIA for the development and clinical production of Kadimastem’s cellular, off-the-shelf AstroRx® product are a clear recognition of the company's innovative technology. Astrocytes, the support cells in the nervous system, which are the basis for the AstroRx® product, have enormous therapeutic potential to protect all types of nerve cells. We are working hard to bring a product to market that will help to improve the lives of ALS patients worldwide as well as to development this therapy for other neurodegenerative diseases such as multiple sclerosis and glaucoma." About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Asaf Shiloni +972 73-797-1613 s.bazak@kadimastem.com Company Website https://www.kadimastem.com/

March 03, 2022 08:05 AM Eastern Standard Time

Image

LevLane Advertising Announces SVP, Partnerships and Development

LevLane

LevLane Advertising, a full-service, award-winning advertising agency based in Center City, Philadelphia, has announced Carl Cherkin, former Vice President of Communications and Business Development at Philadelphia Union, as the agency’s first Senior Vice President of Partnerships and Development. LevLane is a nationally recognized agency which offers creative services, brand planning, social media strategy, public relations, analytics, and more. It was founded almost 40 years ago and has grown to employ more than 75 full-time employees today. Bruce Lev, LevLane’s CEO, Chief Creative Officer, and co-founder, said that while driving in new business and expanding the agency’s presence in the region are primary goals for Cherkin, he fully expects him to step in and contribute in areas outside of partnerships and development. “That’s just who Carl is, and the exact reason we brought him onto our team.” In his previous role at Philadelphia Union, Cherkin was a member of the executive team responsible for launching Philadelphia Union, the city’s successful Major League Soccer team, where he remains a consultant, now in his 13 th season with the club. In addition to the ground-breaking launch, he established a number of successful relationships with corporate sponsors, Chambers of Commerce, and a vast and varied array of businesses, while continuing to generate a continuum of profitable business development opportunities at all levels for the club. Prior to his work in business development and communications, he had a successful career spanning decades in journalism and public relations. For Cherkin, the transition from Emmy Award-winning television sportscaster to business development executive was natural. “I’ve spent my entire career making connections and building relationships, it’s what I love to do,” he said. “I am looking forward to being a part of the team that pushes LevLane into its next phase of growth. We have incredible talent here and my hope is that our reputation for attracting creative powerhouses and impressive clientele makes us the number one agency in Philadelphia and mid-Atlantic region.” The agency has experienced steady growth throughout the past several decades—the decision to bring on a senior vice president for partnerships and development ensures that the agency as a whole remains energized. ‘‘This is an exciting time for LevLane and for me as well. I’ve been given a unique opportunity to work in an environment where the culture, already created, is so vitally important. That my lifelong friend Bruce Lev has been the driving force behind that culture, makes it that much more meaningful,” said Cherkin. “It’s incredibly motivating and at the same time challenging, to know that any and all of contributions I make to this extraordinary group of people will continue to enhance the growth and success of LevLane and its clients.” About LevLane LevLane is an award-winning, full-service, independent advertising agency in Philadelphia, PA, that has been building brands that people love for nearly 40 years. Contact Details Lauren Stralo +1 610-401-4825 lstralo@levlane.com Company Website https://www.levlane.com

March 01, 2022 08:07 AM Eastern Standard Time

Image

Global Advanced Metals Declared Conformant to Minerals Due Diligence Audit Standard for Twelve Consecutive Years

Global Advanced Metals

Global Advanced Metals Pty Ltd (GAM), a leading producer of tantalum powders, additive manufacturing powders, and metallurgical products, has successfully undergone conflict minerals due diligence audits by the Responsible Minerals Assurance Process (RMAP) of the Responsible Minerals Initiative (RMI). Following the September 2021 audits, RMAP-RMI has determined GAM Aizu, Japan and Pennsylvania, USA facilities conformant to its audit standard for the twelfth time. “Successful RMI-RMAP audits are a reflection of GAM’s holistic approach to due diligence, which includes strategic engagement and collaboration with organizations like the Public Private Alliance for Responsible Minerals Trade (PPA), the Responsible Minerals Initiative (RMI), and the Organization for Economic Cooperation and Development (OECD) Multi-Stakeholders Group among others.” said Mark Lackey, GAM Vice-President of Global Operations The RMI-RMAP conflict-minerals due diligence audit program is led and supported by a cross section of industries (e.g., Electronics, Aerospace, Automotive), governments, and other stakeholders. Downstream companies rely on the compliance of smelters like GAM to comply with US Dodd-Frank 1502, EU conflict minerals regulations, and other applicable regulations GAM will continue to enhance its management system approach to minerals due diligence through outreach activities such as: the June 2021 presentation at the D. R. Congo National Episcopal Conference Forum on the Management of Natural Resources and the Environment, and engagement with local University students to share the importance of the role of business in promoting ethical sourcing. About GAM A leading conflict-free tantalum producer, GAM has exclusive rights to the world’s largest industrial resources of tantalum ore located in Western Australia. GAM produces conflict-free tantalum powders and metallurgical products at its Pennsylvania, USA and Aizu, Japan plants for a range of industries including electronics, aerospace, automotive, medical and chemical processing. GAM’s smelting facilities in Japan and the USA were first declared “Conflict-Free” in 2010 under the former EICC/GeSI Conflict-Free Sourcing Initiative (CFSI) audit program and continue to maintain their conformance to the current (RMAP) standard. About RBA, RMI and RMAP The Responsible Business Alliance—RBA was formerly known as the Electronic Industry Citizenship Coalition—EICC, The Responsible Minerals Initiative (RMI) was formerly known as the Conflict Free Sourcing Initiative—CFSI, and The Responsible Minerals Assurance Process—RMAP was formerly known as the Conflict Free Smelter Program—CFSP. Contact Details Global Advanced Metals Jean-Paul Meutcheho +1 610-369-8165 JMeutcheho@globaladvancedmetals.com Company Website https://globaladvancedmetals.com/

March 01, 2022 08:03 AM Eastern Standard Time

G Medical Innovations’ G Medical Tests and Services to Expand COVID-19 Testing to 150+ Additional Locations Across California via a $5.2 Million Cash Purchase

G Medical Innovations Holdings

G Medical Tests and Services, Inc., a wholly-owned subsidiary of G Medical Innovations Holdings Ltd. (NASDAQ: GMVD), announce today that it has expanded its COVID-19 testing services to more than 150+ additional locations across California. The new testing sites include theme parks, schools, commercial properties, office complexes, public buildings, and mobile facilities. G Medical acquired the business conducting testing at the locations for a total of $5.2 million in cash, to be paid out in milestones. The new sites will enable processing of more than 200,000 COVID-19 PCR and rapid antigen/flu tests, with anticipated revenues of $20 million over the next several months - with longer-term growth expected via direct-to-consumer health solutions. The company also reports it has repaid $2.5 million in cash on a $5 million convertible loan issued by Lind Partners. G Medical expects to process more than 200,000 COVID-19 PCR and rapid antigen/flu tests from the new sites, which will generate anticipated revenues of more than $20 million for G Medical Tests and Services in the next several months. The need for convenient COVID-19 PCR, Rapid Antigen/Flu testing, personal healthcare monitoring continues along with the company’s Prizma Care remote patient monitoring directly to consumers. “Our sites create synergies between the ongoing need for testing and remote patient monitoring. The new locations will support our continued investment in direct-to-consumer infrastructure,” said Dr. Yacov Geva, President, and CEO of G Medical Innovations. “COVID-19 is now part of the fabric of our daily lives, and taking control of one’s own health, including daily monitoring of vital signs with our Prizma is more important than ever.” About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial-stage healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses milestone payments, that it expects to process more than 200,000 COVID-19 PCR and rapid antigen/flu tests from the new sites and anticipated revenue. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, the registration statement on Form F-1 filed on February 14, 2022 (registration no. 333-262724) and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Contact Details G-Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

March 01, 2022 07:00 AM Eastern Standard Time

Covid Testing the Right Way and How to Avoid Scams

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/ZyvwNXn2NSo Testing for Covid-19 is now a daily part of many of our lives. Testing to go to work, school, travel, concerts, and most importantly, to stay healthy. But not all tests or testing centers are created equally. There are still many unanswered questions we have on the best ways to stay safe and healthy. With so much uncertainty its time to turn to an expert for insights and information on how to do covid testing the right way and avoid scams. On February 16 th Dr Emily Volk, President of the College of American Pathologists conducted a nationwide media tour. Topics that Dr Volk discussed included: What people need to know to administer an at home test properly Why it’s important that any collection center or laboratory doing COVID testing is accredited, adhering to the very highest standards Are rapid antigen tests more accurate than PCR tests and when to get one or the other Questions we should be asking medical professionals For more information, visit newsroom.cap.org About the College of American Pathologists: As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 22, 2022 01:26 PM Eastern Standard Time

Video

Modivcare Launches Non-Emergency Medical Transportation Provider Academy to Champion Success and Engagement

Modivcare

Modivcare Inc. (“Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions focused on improving patient outcomes, today announced the launch of Modivcare Academy. The innovative program supports transportation providers who own, work for, or operate non-emergency medical transportation (NEMT) companies by providing education, networking opportunities, and training resources. “The introduction of Modivcare Academy is an extension of our purpose, to ensure greater access to care by serving the needs of our communities,” said Daniel Greenleaf, President and CEO of Modivcare. “Our unique program, offered to emerging NEMT companies that contract with us, supports the ongoing business success of transportation providers who are a driving force for positive change within their communities.” Modivcare Academy empowers drivers with information and insights about the latest innovative technology, provides industry best-practices training, and offers resources to support running an NEMT business. The program was kicked-off in Chicago at the December 2021 inaugural Modivcare Academy event that featured subject matter experts offering insights about strategic growth, marketing and sales, customer engagement, operations, financial management, and technology adoption. “We are strongly committed to investing in the success of transportation providers because they serve a critical role in breaking down the barriers that stand in the way of access to care,” added Greenleaf. “Our transportation providers represent a broad and diverse pool of businesses, including disadvantaged, small, minority, and women-owned firms who are committed to providing safe and reliable transportation to the patients we jointly serve. We were overwhelmed by the positive response to our Chicago event and look forward to hosting future events in other communities in 2022.” “As transportation providers, we have faced many COVID-19 challenges, but we have stayed focused and have overcome these hurdles by concentrating on our patients,” said Brisa Berumen-Dixon, a transportation provider with Seabreeze NEMT, Rockford, Illinois. “The most rewarding part of what we do is improving the quality of life for individuals within our hometown communities, which is made possible through our relationship with Modivcare.” To further improve the driver experience and support their business success, Modivcare also launched a “Voice of the Customer” survey program to collect real-time feedback and a Transportation Advisory Council to support the needs of transportation providers. Modivcare’s non-emergency medical transportation services provide access to safe, reliable rides to health services. Working with local, community-based transportation providers, Modivcare is the largest broker of NEMT in the nation and brings more than 35 years of experience to its more than 6,500 transportation providers and provides more than 75 million trips annually to 30 million patients across the nation. Modivcare Academy empowers drivers with information and insights about the latest innovative technology, provides industry best-practices training, and offers resources to support running an NEMT business. The program was kicked-off in Chicago at the December 2021 inaugural Modivcare Academy event that featured subject matter experts offering insights about strategic growth, marketing and sales, customer engagement, operations, financial management, and technology adoption. # # # # About Modivcare Modivcare Inc. (“Modivcare”) (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal and home care, remote patient monitoring, medication management and nutritional meal delivery. Modivcare also holds a minority equity interest in CCHN Group Holdings, Inc. and its subsidiaries (“Matrix Medical Network”), which partners with leading health plans and providers nationally, delivering a broad array of assessment and care management services to individuals that improve health outcomes and health plan financial performance. To learn more about Modivcare, please visit www.modivcare.com. Contact Details Kate Zerone Senior Manager, Communications kate.zerone@modivcare.com Kim Warth Amendola Communications kwarth@acmarketingpr.com

February 22, 2022 09:30 AM Eastern Standard Time

Image

Brush Up on Oral Health: Technology For Your Mouth Leading To Healthy, Confident Smiles

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/UIgoM06hR04 How do you get that ‘fresh from the dentist’ clean feeling on the 360+ days you’re not at the dentist? You turn to a revolutionary kit that integrates advanced technology to deliver brighter, whiter smiles and cleaner, healthier teeth. The result is that consumers look and feel their best and enjoy greater confidence as they go about their day. Built by dental professionals, izzoTM was developed by fourth-generation family-owned Premier Dental, a global developer and manufacturer of dental and medical products that has been in business for 100+ years, with a presence in 76 countries. Julie Charlestein, the President and CEO of Premier Dental, conducted a nationwide media tour to discuss the launch of izzo TM, an innovative new direct to consumer initiative designed to elevate at-home oral care. While brushing your teeth regularly is certainly important, izzo TM is the first and only 4-in-1 oral care system that goes significantly beyond just the typical toothbrush to give your teeth a whole new level of clean. izzo is technology for your mouth leading to healthy, confident smiles. izzo not only helps you brush effectively, it helps you polish to remove surface stains for a brighter, whiter smile; scale to remove plaque and debris between teeth; and sanitize your brush to ensure it’s germ-free for your next use. Best of all, it gives you that ‘fresh from the dentist’ clean feeling and a healthy confidence to look and feel your best. The revolutionary izzo system is currently available online for purchase at www.izzosmile.com for $129.95. For more information or to read first-hand product reviews, please visit www.izzosmile.com. About izzo TM izzo TM is the revolutionary 4-in-1 home oral care system that helps consumers look and feel their best through healthier, whiter smiles. izzo includes a toothbrush, polishing system (polisher & enamel polishing paste), scaler and sanitizer. Made in partnership with Premier ® Dental Products Company, a 4th generation, family-run business established in 1913, izzo reflects the knowledge of over 100 years in developing professional-grade oral care products. This differentiated product introduces innovative in-home dental care directly to consumers through an easy-to-use kit and a convenient Subscribe & Save program. For more information, please visit www.izzosmile.com. About Premier Dental ® Products Company Premier Dental ® is a global privately-held business dedicated to delivering inspired solutions for daily dentistry. Dental professionals have turned to Premier for over 100 years as a leader in bringing innovative products to market that improve their daily procedures, practices and patient outcomes. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 18, 2022 01:54 PM Eastern Standard Time

Video

1 ... 159 160 161 162 163 ... 211